» Articles » PMID: 28476287

Severe Cutaneous Adverse Reactions to Drugs

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2017 May 7
PMID 28476287
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

During the past decade, major advances have been made in the accurate diagnosis of severe cutaneous adverse reactions (SCARs) to drugs, management of their manifestations, and identification of their pathogenetic mechanisms and at-risk populations. Early recognition and diagnosis of SCARs are key in the identification of culprit drugs. SCARS are potentially life threatening, and associated with various clinical patterns and morbidity during the acute stage of Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reactions with eosinophilia and systemic symptoms, and acute generalised exanthematous pustulosis. Early drug withdrawal is mandatory in all SCARs. Physicians' knowledge is essential to the improvement of diagnosis and management, and in the limitation and prevention of long-term sequelae. This Seminar provides the tools to help physicians in their clinical approach and investigations of SCARs.

Citing Articles

Sézary syndrome mimicking Steven-Johnson syndrome: A case report.

Fan S, Lai K Medicine (Baltimore). 2025; 103(52):e41080.

PMID: 39969314 PMC: 11687997. DOI: 10.1097/MD.0000000000041080.


[Dermatological conditions requiring intensive care treatment].

Marks C, Widmeier E, Marks R, Kardaun S Med Klin Intensivmed Notfmed. 2025; 120(2):170-182.

PMID: 39948146 DOI: 10.1007/s00063-024-01239-4.


Peripheral Blood Mononuclear Cells Cytokine Profile in a Patient with Toxic Epidermal Necrolysis Triggered by Lamotrigine and COVID-19: A Case Study.

Martinez-Fierro M, Garza-Veloz I, Zorrilla-Alfaro S, Campuzano-Garcia A, Rodriguez-Borroel M Int J Mol Sci. 2025; 26(3).

PMID: 39941142 PMC: 11818212. DOI: 10.3390/ijms26031374.


Pharmacogenomics predictors of aromatic antiepileptic drugs-induced SCARs in the Iraqi patients.

Ahmed A, Mohamed Noor D, Sabbah M, Musa N, Daud N Heliyon. 2025; 11(1):e41108.

PMID: 39811327 PMC: 11732454. DOI: 10.1016/j.heliyon.2024.e41108.


Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess.

Huang Y, Xu M, Ma X, Wang W, Shen C, Liu F Front Pharmacol. 2024; 15:1503154.

PMID: 39712492 PMC: 11659001. DOI: 10.3389/fphar.2024.1503154.